 When Mylan expanded internationally , Bresch noticed that Mylan 's US @-@ based pharmaceutical manufacturing plant had full @-@ time staff from the Food and Drug Administration ( FDA ) devoted to it , whereas facilities abroad had not been inspected by the FDA for more than a decade . Bresch persuaded several of Mylan 's competitors to support what became the Generic Drug User Fee Act , which she proposed to lawmakers in 2010 . Under the law the pharmaceutical industry would pay fees of $ 300 million in order to fund FDA inspections of foreign drug manufacturing facilities at the same rate as US @-@ based facilities . To advocate for the new law , she made regular visits to Washington , D.C. , and sponsored a whitepaper . The Generic Drug User Fee Act of 2012 was passed on July 9 , 2012 and required FDA inspections of pharmaceutical manufacturing locations abroad if they are importing into the US . 
